Venaxis Inc  

(Public, NASDAQ:APPY)   Watch this stock  
Find more results for APPY
+0.03 (0.84%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.51 - 3.70
52 week 1.60 - 6.65
Open 3.59
Vol / Avg. 135,600.00/21,966.00
Mkt cap 14.28M
P/E     -
Div/yield     -
EPS -1.55
Shares 3.88M
Beta 1.60
Inst. own 7%

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -8637.51%
Operating margin - -8628.77%
EBITD margin - -8193.01%
Return on average assets 11.41% -35.32%
Return on average equity 13.71% -44.06%
Employees 5 -
CDP Score - -


1585 South Perry Street
United States - Map
+1-303-7942000 (Phone)
+1-303-7988332 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Venaxis, Inc. (Venaxis) is an in vitro diagnostic company that is focused on commercializing its blood-based test to serve as an adjunctive test in the diagnosis and treatment of acute appendicitis in children, adolescent and young adults. The Company's test, the APPY1 Test, is a blood test panel for aiding in identifying patients in the emergency department that are at low risk for acute appendicitis. The APPY1 System consists of a small fluorometer (APPYReader Instrument) and consumable test products (APPYReader QC Cassette, APPY1 Controls and APPY1 Test). The APPYReader Instrument measures fluorescence from the APPY1 Test cassette and the APPYReader QC Cassette, the APPYReader QC Cassette enables for functioning of the APPYReader Instrument, and the APPY1 Controls enable functioning of the APPY1 Test components. The APPY1 Test combines the concentrations of over three analytes, such as white blood cell count, C-reactive protein and Venaxis' myeloid-related protein 8/14.

Officers and directors

Stephen T. Lundy President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Jeffrey G. McGonegal Chief Financial Officer, Corporate Secretary
Age: 64
Bio & Compensation  - Reuters
Gail S. Schoettler Ph.D. Non-Executive Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Susan A. Evans Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Daryl Jay Faulkner Independent Director
Age: 66
Bio & Compensation  - Reuters
David E. Welch Independent Director
Age: 68
Bio & Compensation  - Reuters
Stephen A. Williams M.D. Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters